Wei Wei

Ms. Wei Wei


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2021 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
PDF file
WWWei Wei
Wei Wei
XYXu Yang
Xu Yang
Introduction. A Noninvasive diagnosis model for digestive diseases is the vital issue for the current clinical research. Our systematic review is aimed at demonstrating diagnosis accuracy between the BP-ANN algorithm and linear regression in digestive disease patients, including their activation function and data structure. Methods. We reported the systematic review according to the PRISMA guidelines. We searched related articles from seven electronic scholarly databases for comparison of the diagnosis accuracy focusing on BP-ANN and linear regression. The characteristics, patient number, input/output marker, diagnosis accuracy, and results/conclusions related to comparison were extracted independently based on inclusion criteria. Results. Nine articles met all the criteria and were enrolled in our review. Of those enrolled articles, the publishing year ranged from 1991 to 2017. The sample size ranged from 42 to 3222 digestive disease patients, and all of the patients showed comparable biomarkers between the BP-ANN algorithm and linear regression. According to our study, 8 literature demonstrated that the BP-ANN model is superior to linear regression in predicting the disease outcome based on AUROC results. One literature reported linear regression to be superior to BP-ANN for the early diagnosis of colorectal cancer. Conclusion. The BP-ANN algorithm and linear regression both had high capacity in fitting the diagnostic model and BP-ANN displayed more prediction accuracy for the noninvasive diagnosis model of digestive diseases. We compared the activation functions and data structure between BP-ANN and linear regression for fitting the diagnosis model, and the data suggested that BP-ANN was a comprehensive recommendation algorithm.

WWWei Wei
Wei Wei
QWQinmei Wu
Qinmei Wu
JZJialing Zhou
Jialing Zhou
YKYuanyuan Kong
Yuanyuan Kong
HYHong You
Hong You
Background: The clinical efficacy of nucleos(t)ide analogues (NAs) combined with interferon (IFN) therapy vs. NAs monotherapy for chronic hepatitis B (CHB) remains inconclusive. The aim of this meta-analysis was to determine whether the NAs plus IFN regimen offers synergistic efficacy that justifies the cost and burden of such a combination therapy in CHB patients. Methods: Related publications covering the period of 1966 to July 2014 were identified through searching MEDLINE, EMBASE, Cochrane library, Chinese Biomedical Literature Database, WANFANG, and CNKI database. A total of 17 studies were enrolled, including 6 in English and 11 in Chinese. Then, we established a final list of studies for the meta-analysis by systematically grading the quality and eligibility of the identified individual studies. We used hepatitis B antigen (HBeAg) loss, HBV-DNA undetectable rate, HBeAg seroconversion, hepatitis B surface antigen (HBsAg) loss, HBsAg seroconversion, and histological score at the end of treatment for efficacy evaluation. A quantitative meta-analysis (Review Manager, Version 5.1.0) was performed to assess the differences between NAs and IFN combination therapy and NAs monotherapy. Results: Our analysis demonstrated that HBeAg loss (RR = 1.73, 95% CI = 1.32–2.26, p < 0.001), HBV-DNA undetectable rate (RR = 1.58, 95% CI = 1.22–2.04, p < 0.001), HBeAg seroconversion (RR = 1.68, 95% CI = 1.36–2.07, p < 0.001), and HBsAg loss (RR = 2.51, 95% CI = 1.32–4.75, p < 0.001) in the combination therapy group were significantly higher than those in the monotherapy group. However, there were no significant differences in HBsAg seroconversion (RR = 4.25, 95% CI = 0.62–29.13, p = 0.14), sustained virological response rates, and biochemical response rates observed between the two groups. The results showed that the combination therapy group had more improved HBV histology than the NAs monotherapy group (RR = 1.14, 95% CI = 0.93–1.39, p = 0.22). Conclusions: NAs and IFN or Peg-IFN combination therapy had a better efficacy in terms of HBeAg loss, HBV-DNA undetectable rate, HBeAg seroconversion, and HBsAg loss, compared to the NA monotherapy group at the end of treatment; however, there was no significant difference in HBsAg seroconversion between the two regimens.

21 July 2019 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
PDF file
WWWei Wei
Wei Wei
XWXiaoning Wu
Xiaoning Wu
JZJialing Zhou
Jialing Zhou
YSYameng Sun
Yameng Sun
YKYuanyuan Kong
Yuanyuan Kong
XYXu Yang
Xu Yang
The diagnostic performance of an artificial neural network model for chronic HBV-induced liver fibrosis reverse is not well established. Our research aims to construct an ANN model for estimating noninvasive predictors of fibrosis reverse in chronic HBV patients after regular antiviral therapy. In our study, 141 consecutive patients requiring liver biopsy at baseline and 1.5 years were enrolled. Several serum biomarkers and liver stiffness were measured during antiviral therapy in both reverse and nonreverse groups. Statistically significant variables between two groups were selected to form an input layer of the ANN model. The ROC (receiver-operating characteristic) curve and AUC (area under the curve) were calculated for comparison of effectiveness of the ANN model and logistic regression model in predicting HBV-induced liver fibrosis reverse. The prevalence of fibrosis reverse of HBV patients was about 39% (55/141) after 78-week antiviral therapy. The Ishak scoring system was used to assess fibrosis reverse. Our study manifested that AST (aspartate aminotransferase; importance coefficient = 0.296), PLT (platelet count; IC = 0.159), WBC (white blood cell; IC = 0.142), CHE (cholinesterase; IC = 0.128), LSM (liver stiffness measurement; IC = 0.125), ALT (alanine aminotransferase; IC = 0.110), and gender (IC = 0.041) were the most crucial predictors of reverse. The AUC of the ANN model and logistic model was 0.809 ± 0.062 and 0.756 ± 0.059, respectively. In our study, we concluded that the ANN model with variables consisting of AST, PLT, WBC, CHE, LSM, ALT, and gender may be useful in diagnosing liver fibrosis reverse for chronic HBV-induced liver fibrosis patients.

JZJialing Zhou
Jialing Zhou
XWXiaoning Wu
Xiaoning Wu
WWWei Wei
Wei Wei
HYHong You
Hong You
JJJidong Jia
Jidong Jia
YKYuanyuan Kong
Yuanyuan Kong
Background: The aim of the present study was to compare the efficacy of interferon (IFN) with or without different nucleos(t)ide analogues (NAs). Methods: The PubMed, Wan Fang and CNKI databases were searched to identify relevant trials up to May 2015. Meta-analysis was performed with Review Manager 5.0. The stability and reliability were evaluated by publication bias tests. Results: Fifty-six studies fulfilled the criteria for the meta-analysis. Compared with IFN monotherapy, combination therapy were superior in HBV DNA undetectable rate (Risk Ratio (RR) = 1.55, 95% confidence interval (CI): 1.44–1.66, p < 0.00001), HBeAg and HBsAg loss rate (RR = 1.38, 95% CI: 1.22–1.56, p < 0.00001; RR = 1.69, 95% CI: 1.03–2.78, p = 0.04, respectively) at the end of week 48 treatment. Sub-analysis showed the RRs of virological response for entecavir (ETV), adefovir (ADV), and lamivudine (LAM) were 1.64, 1.61 and 1.52, respectively; RRs of HBeAg loss rate were 1.34, 1.71 and 1.34, respectively. However, at the end of follow-up, IFN plus NAs therapy was better than IFN monotherapy only in terms of HBV DNA undetectable rate (p = 0.0007). Conclusions: Combination therapy was better than IFN monotherapy in virological and serological responses at the end of treatment. After follow-up, only HBV DNA undetectable rate was superior for combination therapy.

11 September 2026 in Current Medical Imaging
Verified
Journal Article
Closed access
PDF file
WWWei Wei
Wei Wei
WZWuyan Zhao
Wuyan Zhao
YYYing Yan
Ying Yan
ZWZheng Wang
Zheng Wang
HJHanzhu Jia
Hanzhu Jia
XWXuan Wei
Xuan Wei
Introduction: To investigate the model-inferred dependency pattern of iron deposition in the brain of patients with Parkinson's Disease (PD). Materials and Methods: Clinical and imaging data of 25 patients with PD and 36 Healthy Controls (HCs) were collected between January and December 2021. Iron deposition in the brain was quantified using Quantitative Susceptibility Mapping (QSM). An integrated causal learning workflow, combining GESbased causal discovery, causal effect estimation, and refutation analysis, was used to explore the causal relationships between clinical data and image characteristics and estimate their causal effects. Results: Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) scores were significantly greater in the PD group than the HC group (P = 0.003; P < 0.001). Timed Up and Go Test (TUG) and Berg Balance Scale (BBS) scores were lower in the PD group than in the HC group (P < 0.001; P < 0.001). The integrated causal learning workflow suggested a cross-sectional, model-inferred directional dependency structure with TH occupying an upstream position and downstream dependencies involving PUT, CN, RN, SN, and GP. Discussion: The iron deposition tissues in different regions of the brains of patients with PD exhibit a structured dependency pattern, which is of great significance for proposing hypotheses regarding the mechanism of iron deposition related to PD. Conclusion: The integrated causal learning workflow combined with QSM may help explore cross-sectional dependency patterns of brain iron deposition in patients with PD. These findings provide a biologically interpretable and hypothesis-generating workflow for understanding PD-related iron deposition patterns and may assist in early clinical detection of PD, rapid determination of its course, and timely administration of interventions and treatments.